Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
This study has been withdrawn prior to enrollment.
National Cancer Institute (NCI)
First Posted: July 20, 2012
Last Update Posted: July 7, 2017
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Estimated Study Completion Date:||June 26, 2015|
|Estimated Primary Completion Date:||June 26, 2015 (Final data collection date for primary outcome measure)|